After the 118 PRN interventions, a total of 76 medications were added or dosage modified within 30 days; 47 were targeted HF treatment (25 diuretics, 13 beta blockers, 4 renin–angiotensin–aldosterone system inhibitors, 1 sodium glucose transporter 2 inhibitors, 3 hydral‐nitrates, and 1 mineralocorticoid receptor antagonist) and 6 targeted cardiac arrhythmia management (3 anticoagulants and 3 antiarrhythmics) (Table S3). This evidence concerns the gene NR3C2 and chronic obstructive pulmonary disease.